Lymphoma stem cells: enough evidence to support their existence?

Martínez-Climent, José A.; Fontán, Lorena; Gascoyne, Randy D.; Siebert, Reiner; Prósper, Felipe

doi:10.3324/haematol.2009.013318

Cited by 54 publications

(41 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…68,69 Finally, several recent developments have pointed toward the existence of "lymphoid cancer stem cells," which may represent highly desirable targets to achieve a definitive cure in these malignancies. [70][71][72] Although several European groups have already made outstanding contributions to this field, in part within large international consortia, further Section 2. Malignant lymphoid diseases achievements will only be possible if major investments can be realized.…”

Section: The Eha Roadmap For European Hematology Researchmentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

T he European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at €23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

show abstract

Section: The Eha Roadmap For European Hematology Researchmentioning

confidence: 99%

The European Hematology Association Roadmap for European Hematology Research: a consensus document

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Similar to normal hematopoiesis, leukemia (also known as "blood cancer" characterized by uncontrolled proliferation of blood cells) is caused by leukemia stem cells (LSCs), whose progenitors are capable of self renewal, see Figure 1, [32,41]. There are both acute and chronic versions of the myelogenous and lymphoblastic leukemia (AML, CML, ALL, CLL).…”

Section: Mathematical Model Of Cell Dynamics In Leukemia 21 Biologimentioning

confidence: 99%

“…Since then, many other cancer stem cells (CSCs) have been identified: breast cancer in 2003, brain tumor in 2004, and later, colon, prostate, lung and liver CSCs have followed, [12]. Recently, it has been reported that, in some types of cancers, progenitor cells may become stem cells (this is called plasticity), [27], but for the mathematical model of cell dynamics in leukemia our basis will be Figure 1, which is a simplified version of Figure 1 of [41], where further justifying references can be found.…”

Section: Mathematical Model Of Cell Dynamics In Leukemia 21 Biologimentioning

confidence: 99%

Stability Analysis of Cell Dynamics in Leukemia

Özbay

Bonnet

Benjelloun

et al. 2012

Math. Model. Nat. Phenom.

View full text Add to dashboard Cite

Abstract. In order to better understand the dynamics of acute leukemia, and in particular to find theoretical conditions for the efficient delivery of drugs in acute myeloblastic leukemia, we investigate stability of a system modeling its cell dynamics. The overall system is a cascade connection of sub-systems consisting of distributed delays and static nonlinear feedbacks. Earlier results on local asymptotic stability are improved by the analysis of the linearized system around the positive equilibrium. For the nonlinear system, we derive stability conditions by using Popov, circle and nonlinear small gain criteria. The results are illustrated with numerical examples and simulations.

show abstract

“…Recently, it has been proposed that commited lymphoid progenitors/precursor cells with an active V-D-J recombination program are the initiating cells of follicular lymphoma when targeted by immunoglobulin-gene translocations in the bone marrow. However, these pre-malignant lymphoma initiating cells cannot drive complete malignant transformation, requiring additional cooperating mutations in specific stem cell programs to be converted into the lymphoma originating cells able to generate and sustain lymphoma development [12].…”

Section: The Cell Of Origin Of Follicular Lymphomamentioning

confidence: 99%